Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion.

Tanaka Y, Koido S, Xia J, Ohana M, Liu C, Cote GM, Sawyer DB, Calderwood S, Gong J
J Immunol. 2004 172 (12): 7848-58

PMID: 15187169 · DOI:10.4049/jimmunol.172.12.7848

CD8+ CTL are the predominant tumoricidal effector cells. We find, however, that MHC class I-deficient mice depleted of CD8+ T cells are able to mount an effective antitumor immunity after immunization with fused dendritic/tumor cells. Such immunity appears to be mediated by the generation of phenotypic and functional CD8+ CTL through CD4+ to CD8+ conversion, which we have demonstrated at the single cell level. CD4+ to CD8+ conversion depends on effective in vivo activation and is promoted by CD4+ T cell proliferation. The effectiveness of this process is shown by the generation of antitumor immunity through adoptive transfer of primed CD4 T cells to provide protection against tumor cell challenge and to eliminate established pulmonary metastases.

MeSH Terms (16)

Adoptive Transfer Animals Antigens, Neoplasm Cancer Vaccines CD4-Positive T-Lymphocytes CD8-Positive T-Lymphocytes Cell Lineage Histocompatibility Antigens Class I Immunity Immunization Lymphocyte Activation Mice Mice, Inbred C57BL Mice, Knockout Mice, Transgenic T-Lymphocytes, Cytotoxic

Connections (1)

This publication is referenced by other Labnodes entities: